Navigation Links
Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
Date:5/31/2012

BOSTONA novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions will report at the annual meeting of the American Society of Clinical Oncology (ASCO) June 1-5 in Chicago.

Pasi A. Jnne, MD, PhD, scientific co-director of Dana-Farber's Belfer Institute for Applied Cancer Science, will present the findings from the randomized phase II study (abstract 7503) on Monday, June 4, 3 p.m. CT, E Hall D2, McCormick Place.

The study involved 87 non-small cell lung cancer (NSCLC) patients whose tumors carry a mutation in the gene KRAS. Such tumors account for about 20 percent of NSCLC cases, but no targeted therapy has proved effective against them in previous clinical research. The drug under investigation, selumetinib, doesn't attack KRAS directly, but interferes with one of its molecular henchmen, a protein called MEK.

Participants in the study all had advanced stages of the disease. They received the standard chemotherapy agent docetaxel in combination with either selumetinib or a placebo.

By many measures the rate and duration of response to treatment, change in tumor size, and proportion of patients alive and showing no signs of advancing disease -- the group receiving selumetinib did significantly better than the other group. Most clinically significant were the improved rate of response to treatment (37 percent compared to 0 percent in the placebo arm) and prolonged progression-free survival (5.3 months compared to 2.1 months in the placebo arm). Although patients in the selumetinib group survived longer, on average, than those in the placebo group 9.4 months compared to 5.2 months the improvement was not considered statistically significant.

"This clinical trial demonstrates that a combination of chemotherapy and selumetinib is significantly better than chemotherapy alone for this group of patients better in terms of tumor response to therapy and in terms of survival times prior to advance of the disease," says Jnne. "It suggests that for the first time we may have an effective treatment for KRAS-mutant lung cancer, which is the largest single subtype of the disease. These impressive clinical findings not only have implications for the treatment of lung cancer but all cancers that harbor KRAS mutations, including pancreatic and colorectal cancer."

Some side effects, such as neutropenia (a white blood cell deficiency), loss of strength, acne, and respiratory problems were more common in the selumetinib group than the other, but the rate of patients dropping out of the study because of severe side effects was similar for both groups.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Humans Can Sniff Out Old Age in Others, Study Shows
2. Infant Smarts Similar With Different Types of Formula: Study
3. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
4. Cooling Helps Oxygen-Deprived Newborns: Study
5. Immigrant women giving birth in Spain suffer great stress, a study warns
6. Once-Obese Women Still Face Stigma, Study Finds
7. Surly People Tend to Like Fierce Dogs, Study Shows
8. Nordic Walking a Winner for Heart Failure Patients, Study Says
9. Common Painkillers May Help Prevent Skin Cancer: Study
10. Antioxidant shows promise as treatment for certain features of autism, Stanford study finds
11. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... ... A fifth-year speaker at the 2017 LBG Advisors Benefits Symposium , ... the state of the Affordable Care Act (ACA) with the new administration in place. ... hosted at Disney’s Grand Californian Hotel & Spa from February 26-28. It is designed ...
(Date:1/24/2017)... ... January 24, 2017 , ... The health ... Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 was no ... Mainly, people are witnessing higher deductibles, rising premiums, and few choices with their ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The Cruise ... Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... North American travel partners for the year based on overall business growth in revenue ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... solutions, announced that it has officially formed a distribution partnership with Byers ... the industrial odor management industry. , Through the agreement, OMI Industries formulated a ...
(Date:1/24/2017)... Chapel Hill, N.C. (PRWEB) , ... January 24, ... ... the Trump Administration is the focus of a new report from the ... Carolina Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 2017  BioSpecifics Technologies Corp. (NASDAQ: ... originated and continues to develop collagenase based-therapies ... collagenase clostridium histolyticum, or CCH, marketed as ... ®  in Europe, today announced that BioSpecifics, President, Tom ... the upcoming NobleCon13 - Noble Capital Markets, ...
(Date:1/24/2017)... MOINES, Iowa , Jan. 24, 2017 When tragedy ... who the victim is, what conditions they have, and who back ... was created—to keep loved ones informed about the safety of their ... information they need about victims in times of crisis. ... If you find yourself or ...
(Date:1/24/2017)... PORTLAND, Oregon and PUNE, India ... A new report published by Allied Market Research, titled, ... Vegetables, Bakery & Confectionary, Dairy & Frozen Dessert, Meat, ... Industries): Global Opportunity Analysis and Industry Forecasts, 2014-2022," projects ... to garner $426,275 million by 2022, growing at a ...
Breaking Medicine Technology: